NCT07054489 · David Lanfear
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
(UPBEAT)
What this study is about
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
View original scientific description
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age 18-89 years
- Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
- Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
- Expected ability to fully participate in study (can tolerate study processes, no long travel)
Exclusion criteria
- Unable to provide informed consent
- Previous documented EF =\< 35%
- Currently on BB =\>25% target dose
- Uncontrolled hypertension (systolic BP \> 180 at enrollment)
- Has contraindications to all BB or intolerance to metoprolol
- Systolic BP \< 100 or heart rate \<70
- Current cancer requiring active treatment
- Heart transplant or LVAD or expected in the next year
- Life expectancy \< 1 year for any reason
- Dialysis dependence or ESRD
- MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future
- Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
- If PI decides for any reason participation in trial is not in best interest of the patient
- Has a contraindication to completing MRI procedures
Where
- Detroit, Michigan
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 7, 2026 · Source of record for eligibility and locations